Figures & data
Figure 1 The effect of 5-AZA and TSA on the growth and viability of human lung cancer cells’ growth and viability.
Notes: (A) 5-AZA inhibited the viability of NCI-H1975 and NCI-H1299 cells at days 2 and 3. Cells were treated with 0, 0.1, 1, 5, 10, and 20 µM 5-AZA. (B) 5-AZA inhibited the proliferation of NCI-H1975 and NCI-H1299 cells at day 3. (C) TSA decreased the viability of NCI-H1975 and NCI-H1299 cells at day 2. (D) TSA decreased the growth of NCI-H1975 and NCI-H1299 cells at days 2 and 3. (E) The joint application of 5-AZA and TSA significantly inhibited the viability of NCI-H1975 and NCI-H1299 cells. *P<0.05, **P<0.01. N=3.
Abbreviations: 5-AZA, azacitidine; Rel, relative; TSA, trichostatin A.
Abbreviations: 5-AZA, azacitidine; Rel, relative; TSA, trichostatin A.
Figure 2 TSA and 5-AZA regulate the expression of TFF1 and VCAM1.
Notes: (A) The joint application of 5-AZA and TSA influenced TFF1 and VCAM1 expression. (B) The mRNA expression of TFF1 and VCAM1 gene increased with the application of 5-AZA and TSA. **P<0.01.
Abbreviations: 5-AZA, azacitidine; Rel, relative; TSA, trichostatin A; Vec, vector.
Abbreviations: 5-AZA, azacitidine; Rel, relative; TSA, trichostatin A; Vec, vector.
Figure 3 TSA and 5-AZA decreased the tumorigenic ability of NCI-H1975 cells in vivo.
Abbreviations: 5-AZA, azacitidine; TSA, trichostatin A.
